Congenital hypothyroidism: a treatable cause of intellectual disability that screening prevents

What is congenital hypothyroidism?

Congenital hypothyroidism (CH) means a baby is born with a thyroid gland that does not work adequately, or that is absent. The thyroid gland produces thyroxine (T4), a hormone essential for brain development in the first years of life and for physical growth throughout childhood. Without it, both the brain and the body fail to develop normally.

In most cases, the cause is a developmental abnormality of the thyroid gland itself during fetal life. The gland may have formed in the wrong position (ectopic thyroid), be smaller than normal (hypoplastic), or be entirely absent (athyreosis). In a smaller proportion of cases, the gland is present but the enzymes needed to produce thyroid hormone do not function correctly. This second group is often inherited in an autosomal recessive pattern and can recur in siblings.

The condition affects approximately 1 in 2000 to 4000 newborns in iodine-sufficient populations. In iodine-deficient areas, which include parts of the Middle East and Africa, the rate may be higher because iodine deficiency prevents adequate hormone synthesis independently of gland structure. A 2016 study from Abu Dhabi in the UAE documented local characteristics of congenital hypothyroidism in the region, finding patterns broadly consistent with international data while noting regional features including a higher proportion of ectopic glands.

Why the newborn looks normal at first

This is the fundamental reason that newborn screening exists and why it cannot be skipped or deferred. During pregnancy, the mother's thyroid hormones cross the placenta and reach the fetus, providing enough hormone to protect fetal brain development for the duration of the pregnancy. At birth, the baby carries a reserve of maternal hormone in its circulation.

After delivery, that maternal supply is cut off. The newborn must now rely on its own thyroid gland. If the gland is absent or severely dysfunctional, circulating T4 begins to fall over the first days and weeks of life. During this early period there are no symptoms. The baby feeds, sleeps and appears healthy. Nothing in a clinical examination would raise suspicion.

As weeks pass without treatment, the falling hormone level begins to affect brain development, which is at its most intense period of activity precisely in these first months of life. The damage that accumulates is not reversible once it has occurred. Research consistently shows that treatment begun before day 13 of life is associated with the best cognitive outcomes. Delay of even a few weeks matters significantly for the child's long-term intellectual development.

Symptoms that eventually appear in an untreated infant include prolonged jaundice, feeding difficulties, excessive sleepiness, constipation, a large tongue, an umbilical hernia, slow reflexes and poor weight gain. By the time these are noticed and acted upon, meaningful cognitive damage may already have occurred. The treatment window for preventing disability is measured in days and weeks, not months.

How newborn screening works

The standard screening method is the heel prick test, also called the newborn bloodspot screen or Guthrie test in some countries. A small drop of blood is taken by a gentle heel prick, usually between day two and day five of life. The blood is absorbed onto a filter paper card and sent to a laboratory where TSH is measured.

TSH (thyroid stimulating hormone) rises when the thyroid gland is underperforming because the pituitary gland responds by sending a stronger signal to try to stimulate it. A high TSH in the newborn's blood in the first days of life is the alert that triggers further testing. Some programmes also measure T4 directly from the same sample to increase sensitivity.

Timing is important. A sample taken in the first 24 hours may give a falsely normal result because there is a physiological surge in TSH immediately after birth that can temporarily mask the underlying deficiency. Waiting until after 48 hours produces a more reliable result. Preterm babies or sick newborns may need a repeat sample at two weeks because their TSH response is sometimes delayed or blunted by their clinical condition.

A 2020 paper in the Annals of the Academy of Medicine Singapore reviewed the evidence base for different screening strategies and confirmed that TSH-based primary screening with T4 as a backup remains the most sensitive approach for detecting primary congenital hypothyroidism in large populations.

What an abnormal screening result means

An abnormal heel prick result is not a confirmed diagnosis. It is an alert that needs urgent follow-up, not a cause for immediate despair. False positives occur, particularly in premature babies, infants who were unwell at the time of testing, or those whose sample was taken very early. A confirmatory venous blood sample measuring TSH and free T4 is the next step.

If the venous sample confirms elevated TSH with low free T4, treatment with levothyroxine begins as soon as possible, ideally within the same day. Treatment does not wait for imaging or genetic results. The priority is starting the hormone before more time is lost. A 2021 review in Neonatal Network confirmed that the speed of treatment initiation is among the strongest predictors of cognitive outcome.

Additional investigations follow but do not delay treatment. A thyroid ultrasound assesses the size and position of the gland. A radionuclide scan (technetium or iodine-123) can identify ectopic tissue, but access to this investigation varies across the region. Genetic testing is relevant when the enzyme-defect form is suspected, because it carries recurrence risk for future pregnancies.

A 2020 review of hypothyroidism management across GCC countries by Alzahrani and colleagues noted that while awareness and screening coverage have improved substantially in the Gulf, gaps remain in standardisation of follow-up protocols across the region.

Levothyroxine treatment: how it is given and monitored

Sodium levothyroxine (Levothyroxine or L-T4) is the synthetic thyroid hormone that replaces what the gland cannot produce. For newborns it comes in tablet form: the tablet is crushed and dissolved in a small amount of breast milk or water, then given to the baby at the start of the first morning feed. It should not be mixed into a full bottle of formula because the calcium in formula reduces absorption.

The starting dose is typically 10 to 15 micrograms per kilogram of body weight per day. The dose is adjusted as the baby grows, guided entirely by blood results rather than symptoms. In the first year, thyroid function tests are repeated frequently, roughly every one to two months, and then less often as the child stabilises.

The treatment target is to keep TSH within the normal range for the child's age, generally below 5 mIU/L in the first year of life, and to keep free T4 in the upper half of the normal range. TSH persistently above target suggests the dose needs increasing. TSH below 0.1 suggests the dose is too high, which carries its own risks to bone density and cardiac rhythm in the long run.

Levothyroxine does not cause dependence and has no harmful effects at the correct dose. It simply replaces a hormone the body cannot make enough of. Families sometimes worry about giving a newborn a daily medicine indefinitely, but it is no different in principle from an insulin-dependent diabetic child receiving insulin. Without the hormone, the child cannot develop normally; with it, development proceeds.

What to expect in the longer term

The long-term outlook for children who are screened, diagnosed and treated early is excellent. Long-term follow-up studies show that children treated from the first weeks of life reach normal or near-normal intellectual development in the great majority of cases. They attend mainstream school, develop social relationships and live independently.

Children with the most severe form of the condition, where the gland is completely absent, or those whose treatment was delayed by several weeks, may experience subtle difficulties in specific cognitive domains such as verbal memory or attention, even with otherwise well-managed treatment. This underscores why the speed of detection and treatment initiation matters so much.

Treatment is lifelong in most cases because the absent or damaged gland does not recover. In the minority of children who have a milder, potentially transient form of the condition, the paediatrician may attempt a trial off medication around age three, with close monitoring, to determine whether the thyroid has resumed adequate function. This is done only under specialist supervision with blood tests at every step.

Supporting the child's development more broadly, through language-rich interaction, reading, play and early stimulation, compounds the benefit of the medication. The families who engage actively with follow-up appointments and medication consistency tend to see the best outcomes.

Iodine in pregnancy: prevention before birth

In iodine-deficient regions, maternal iodine deficiency during pregnancy is a preventable contributor to thyroid problems in newborns. Iodine is a building block of thyroid hormone. If the mother is severely deficient, her ability to supply adequate hormone to the fetus during critical brain development periods is compromised.

The World Health Organization recommends 250 micrograms of iodine per day for pregnant and breastfeeding women, which is higher than the requirement for non-pregnant adults. Iodised salt is a population-level intervention used across much of the Middle East, but its coverage and the actual iodine content of available salt varies. Antenatal vitamins that include iodine provide a more reliable supplement for individual women.

Severe iodine deficiency causing cretinism, the most extreme form of developmental thyroid failure, has been largely eliminated where iodisation programmes are working. But mild to moderate deficiency affecting cognitive development more subtly remains a public health concern in parts of the region. A pregnant woman who is unsure about iodine intake in her diet should raise this with her antenatal care provider.

Excess iodine also carries risk. Exposure to large quantities of iodine-containing contrast agents during imaging procedures, or supplementation far above recommended levels, can suppress fetal thyroid function transiently. This is a less common concern but worth noting in regions where contrast-enhanced imaging during pregnancy is not always tightly monitored.

Is screening available where you are?

National newborn screening programmes covering congenital hypothyroidism are established in Saudi Arabia, UAE, Kuwait, Egypt, Jordan, Morocco, Tunisia and Algeria. In these countries, the test is performed routinely before hospital discharge or at the first outpatient visit. Families typically receive the result within a week.

In other countries in the region, particularly in settings affected by conflict or fragile health systems, routine newborn screening is not reliably available. If you are unsure whether the test was done for your baby, ask directly: was the heel prick test performed? Does it include thyroid screening? When will the result come back?

If the test was not performed and your baby is already more than a week old, do not wait for the screening system. A venous blood draw for TSH and free T4 is a simple, safe and inexpensive test that any paediatric clinic can perform. Catching the condition at two weeks rather than two months is still far better than missing it entirely.

Community awareness is itself a preventive intervention. A mother who knows about this test asks for it. Sharing this information with family members and friends who are expecting is one of the most directly useful things a person with health literacy can do.

Sources

• Wassner AJ: Congenital Hypothyroidism, Clinics in perinatology, 2018
• Bowden SA, Goldis M: Congenital Hypothyroidism, StatPearls, 2026
• Deeb A, Elkadry I, Attia S et al: Biochemical, radiological, and genetic characterization of congenital hypothyroidism in Abu Dhabi, United Arab Emirates, Journal of pediatric endocrinology and metabolism, 2016
• Lau CS, Joseph R, Aw TC et al: Screening for Congenital Hypothyroidism, Annals of the Academy of Medicine Singapore, 2020
• Brady J, Cannupp A, Myers J et al: Congenital Hypothyroidism, Neonatal network, 2021
• Alzahrani AS, Al Mourad M, Hafez K et al: Diagnosis and Management of Hypothyroidism in Gulf Cooperation Council (GCC) Countries, Advances in therapy, 2020
• World Health Organization: Newborn health fact sheet